CSI Market
Sign In | Register

Biodesix Inc (BDSX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access BDSX quarterly Cash Flow →
Reviewing cash flow figures over time highlights how Biodesix Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-35.27
Depreciation & amortization5.67
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Finite-lived0.11
Provision For Loan Losses Expensed0.18
Inventory Write-down0.05
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation4.14
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.28
Accrued Interest On Notes Payable And Convertible Notes Payable-
Operating Lease Right Of Use Asset Amortization Expense-
Increase Decrease In Contract With Customer Liability0.17
Accretion Reduction Of Lease Right Of Use Assets-
Operating Lease Right Of Use Asset Reduction Accretion Amortization Expense-0.07
Accrued Interest Amortization Of Debt Issuance Costs And Other-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.53
Increase (Decrease) in Accounts Payable and Accrued Liabilities1.86
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-0.38
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.52
Discontinued operations0.00
Net Cash flow from Operating Activities-23.27
Investing Activities
Capital Expenditures-0.26
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net-0.14
Payments To Acquire Oncimmune-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.40
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.03
Long-term debt - borrowings0.00
Long-term debt - repayments-0.02
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock7.32
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.82
Proceeds From Issuance Of Term Loan And Notes Payable10.00
Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan0.50
Payment Of Equity Financing Costs-0.53
Payment Of Deferred Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities16.42
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-23.53
Total Cash Flow-7.26
4 historic quarters locked

Sign in to unlock the full Biodesix Inc cash flow history.

Sign In Create Free Account

About Biodesix Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: bdsx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-076547

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License